Two newer classes of second-line hypoglycemic drugs, glucagon-like peptide-1 (GLP-1) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors, have gained increasing popularity among patients with T2DM.3 The gene discussed is DPP4; the disease is type 2 diabetes mellitus.